Jasper Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen prior to allogeneic transplant for chronic granulomatous disease.
[Jasper Therapeutics, Inc. (Business Wire, Inc.)]
Sorry, but the selected Zotpress account can't be found.
